alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab)

July 2006

A recent analysis is alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab).

These TNF inhibitors are wonder drugs for many patients with rheumatoid arthritis, Crohn's, and other autoimmune diseases.

But there's concern about an increased risk of serious infections and malignancies. Tumor necrosis factor plays a role in fighting infections and killing tumor cells.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote